Aubagio ‘reduces brain volume loss’

Aubagio is an oral treatment approved for MS.

Aubagio ‘reduces brain volume loss’

Postby MSUK » Wed Apr 20, 2016 2:47 am

Aubagio treatment decreased brain volume loss in patients with relapsing-remitting multiple sclerosis (MS) independent of disability progression, a study presented at the 68th annual American Academy of Neurology meeting concluded...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Re: Aubagio ‘reduces brain volume loss’

Postby frodo » Thu May 17, 2018 2:23 am

An independent confirmation: Aubagio seems to delay brain damage under DTI MRI (more sensitive to MS than normal MRI)

https://www.sciencedirect.com/science/a ... 0X18301539

Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures

Objectives

To investigate the effect of teriflunomide on microstructural pathology in the gray matter (GM) and white matter (WM), as measured by changes in brain volume and diffusion-tensor imaging (DTI) in patients with multiple sclerosis (MS).

Methods

30 relapsing MS patients and 20 healthy controls (HCs) were enrolled in the study and followed prospectively for 12 months with clinical and 3T MRI examinations. Of those, 26 MS patients and 18 HCs completed the 6-month and 22 MS and 16 HCs patients the 12-month follow-up. Whole brain, GM, WM and thalamus volumes, and global and tract-based spatial statistics (TBSS) DTI measures of fractional anisotropy, mean, axial and radial diffusivity were obtained in the thalamus and normal appearing WM (NAWM). MRI differences between the groups were compared using non-parametric statistical methods due to sample size limitations, followed by post-hoc covariate-adjusted models.

Results

At baseline, MS patients showed more severe brain volume and DTI measures compared to HCs (p < .05). At follow-up, no significant differences for brain volume and global and TBSS DTI measures between MS patients and HCs were found. No clinical progression or serious adverse events occurred in MS patients over the follow-up.

Conclusions


MS patients did not significantly deteriorate over the follow-up in brain volume or thalamus/NAWM global or TBSS DTI measures, compared to HCs. This suggests that treatment with teriflunomide could potentially slow down accumulation of microstructural tissue damage in the GM and NAWM.
User avatar
frodo
Family Elder
 
Posts: 1098
Joined: Wed Dec 02, 2009 4:00 pm

Re: Aubagio ‘reduces brain volume loss’

Postby NHE » Thu May 17, 2018 5:44 am

frodo wrote: Results

At baseline, MS patients showed more severe brain volume and DTI measures compared to HCs (p < .05). At follow-up, no significant differences for brain volume and global and TBSS DTI measures between MS patients and HCs were found. No clinical progression or serious adverse events occurred in MS patients over the follow-up.

Is this written correctly? At face value, it appears to be stating that MS patients improved to the level of healthy controls! 8O
User avatar
NHE
Volunteer Moderator
 
Posts: 4826
Joined: Sat Nov 20, 2004 4:00 pm


Return to Aubagio (teriflunomide)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service